Government attorneys are asking a North Carolina federal judge to apply a strict legal blueprint borrowed from a completely separate, high-profile case involving Tylenol.
In a national lawsuit, parents claimed taking acetaminophen during pregnancy caused their children to develop autism or ADHD. A higher appeals court recently issued a major ruling on how strictly trial judges must vet medical experts and scientific data before a jury is allowed to hear it. Now, federal lawyers have formally flagged that case for the Camp Lejeune judges, hoping to tighten restrictions on what science is allowed at trial.
If the Camp Lejeune judges accept this Tylenol case ruling, they will be forced to wear two distinct hats during these upcoming bench trials. First, as evidentiary gatekeepers, they would be expected to allow any expert testimony that relies on standard, field-accepted methodologies—even if they personally harbor doubts about the science. Then, as the ultimate triers of fact in place of a jury, the judges would have to weigh those competing scientific arguments during the actual trial to decide which side is ultimately more persuasive.
Read more: Camp Lejeune Justice Act Series
This high-stakes evidentiary move comes as the wider litigation faces immense strain under a mountain of unresolved paperwork. The latest joint status report reveals 3,773 active federal lawsuits, while more than 408,000 individual claims remain clogged in the Navy's administrative backlog. However, missing documentation remains a massive hurdle. Out of more than 400,000 claims filed, the Navy reports that 88 percent still lack the evidence required for final Justice Department approval.
A breakthrough could be on the horizon, though. Both sides are currently analyzing newly digitized military muster-roll records to quickly verify who was present at the base during the contamination period, a process that could dramatically cut through months of red tape.
Actual payouts also remain a severe point of contention. According to federal court filings, one kidney cancer claimant accepted a $100,000 settlement offer from the government, though plaintiffs' attorneys warn that figure should not be considered a fair valuation for similar claims.
Crucial rulings also remain stalled, with the court yet to decide how much money the government can claw back using VA and Medicare offsets, leaving families waiting for answers.
Meanwhile, in the same filings, the victims' legal team accused the government of dragging out proceedings in a separate dispute, using "out-of-context quotations" and filing repetitive briefs to stall the process.
The federal judges overseeing the Lejeune litigation have not yet ruled on the Tylenol precedent or the outstanding procedural motions.
